Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 23297798)

1.

Successful azacitidine treatment with increase of regulatory T cells for relapsed acute myeloid leukemia after allogeneic stem cell transplant.

Yamamoto W, Tachibana T, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H.

Leuk Lymphoma. 2013 Sep;54(9):2079-80. doi: 10.3109/10428194.2013.764420. Epub 2013 Feb 11. No abstract available.

PMID:
23297798
2.

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock CF.

Blood. 2012 Apr 5;119(14):3361-9. doi: 10.1182/blood-2011-09-377044. Epub 2012 Jan 10.

3.

Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).

Ganguly S, Amin M, Divine C, Aljitawi OS, Abhyankar S, McGuirk JP.

Ann Hematol. 2013 Apr;92(4):549-50. doi: 10.1007/s00277-012-1607-y. Epub 2012 Oct 31. No abstract available.

PMID:
23111661
4.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.

Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G.

Leukemia. 2013 Sep;27(9):1910-3. doi: 10.1038/leu.2013.64. Epub 2013 Mar 1. No abstract available.

PMID:
23519388
5.

[Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].

Wang J, Zhou J, Zheng HF, Fu ZZ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1448-52. doi: 10.7534/j.issn.1009-2137.2014.05.050. Chinese.

PMID:
25338605
6.

Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation.

Ustun C, Kalla A, Farrow S, DeRemer DL, Jillella A.

Am J Hematol. 2008 Oct;83(10):825-7. doi: 10.1002/ajh.21267. No abstract available.

PMID:
18767131
7.

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C.

Leukemia. 2012 Mar;26(3):381-9. doi: 10.1038/leu.2011.234. Epub 2011 Sep 2.

8.

Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.

Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, Schaefer-Eckart K, Bornhäuser M, Itzykson R, Germing U, Beelen D, Ehninger G, Fenaux P, Deeg HJ, Adès L; German MDS Study; Cooperative Transplant Study Group; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1415-21. doi: 10.1016/j.bbmt.2012.05.003. Epub 2012 May 11.

9.

Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.

Niscola P, Tendas A, Cupelli L, Giovannini M, Piccioni D, Scaramucci L, Dentamaro T, Del Poeta G, de Fabritiis P.

Acta Haematol. 2015;133(1):64-6. doi: 10.1159/000363643. Epub 2014 Aug 14. No abstract available.

PMID:
25139255
10.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

PMID:
23314834
11.

Studies of decitabine with allogeneic progenitor cell transplantation.

Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian H.

Leukemia. 1997 Mar;11 Suppl 1:S32-4.

PMID:
9130690
12.

Transplantation for MDS in the elderly: more evidence, or more bias?

Cutler C.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1320-1. doi: 10.1016/j.bbmt.2012.06.009. Epub 2012 Jun 29. No abstract available.

13.

Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.

Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M.

Am J Hematol. 2014 Aug;89(8):795-802. doi: 10.1002/ajh.23746. Epub 2014 May 16.

PMID:
24757092
14.

Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.

Villela L, Anders V, Bolaños-Meade J.

Anticancer Drugs. 2010 Apr;21(4):469. doi: 10.1097/CAD.0b013e328335be46. No abstract available.

PMID:
20216343
15.

Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.

Yee KW, Brandwein J, Schimmer AD, Gupta V, Del Bel R, Xu W, Minden MD, Schuh AC.

Br J Haematol. 2014 Jul;166(2):303-6. doi: 10.1111/bjh.12844. Epub 2014 Mar 21. No abstract available.

PMID:
24650042
16.

Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.

Singh SN, Cao Q, Gojo I, Rapoport AP, Akpek G.

Bone Marrow Transplant. 2012 Jul;47(7):1008-9. doi: 10.1038/bmt.2011.210. Epub 2011 Nov 14. No abstract available.

PMID:
22080965
17.

Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.

Wang ES, Zeidan A, Tan W, Wilding GE, Ford LA, Wallace PK, Hahn TE, Battiwalla M, McCarthy PL, Wetzler M.

Leuk Lymphoma. 2012 Oct;53(10):2085-8. doi: 10.3109/10428194.2011.603450. Epub 2011 Sep 6. No abstract available.

PMID:
21740302
18.

Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.

Arellano ML, Langston A, Winton E, Flowers CR, Waller EK.

Biol Blood Marrow Transplant. 2007 Jan;13(1):116-23.

19.

Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.

Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G.

Leuk Res. 2007 Feb;31(2):257-9. Epub 2006 Apr 18.

PMID:
16620971
20.

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.

Sockel K, Wermke M, Radke J, Kiani A, Schaich M, Bornhäuser M, Ehninger G, Thiede C, Platzbecker U.

Haematologica. 2011 Oct;96(10):1568-70. doi: 10.3324/haematol.2011.044388. Epub 2011 Jul 12. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk